Share

January 2020; 7 (1) Correction

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS

First published December 5, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000657
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
187

Share

See original article:

Article Information

vol. 7 no. 1 e657
DOI: 
https://doi.org/10.1212/NXI.0000000000000657
PubMed: 
31806686
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published December 5, 2019.
Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    View Full Text

    Article usage

    Article usage: December 2019 to April 2022

    AbstractFullPdfSource
    Dec 2019410529Highwire
    Jan 2020410014Highwire
    Feb 202013310Highwire
    Mar 20201165Highwire
    Apr 20200153Highwire
    May 20201178Highwire
    Jun 20200113Highwire
    Jul 20200157Highwire
    Aug 2020372Highwire
    Sep 20203155Highwire
    Oct 20201163Highwire
    Nov 2020086Highwire
    Dec 2020182Highwire
    Jan 2021194Highwire
    Feb 20210136Highwire
    Mar 20210123Highwire
    Apr 2021235Highwire
    May 2021061Highwire
    Jun 20210143Highwire
    Jul 20211413Highwire
    Aug 2021032Highwire
    Sep 2021062Highwire
    Oct 20211617Highwire
    Nov 20210213Highwire
    Dec 20210115Highwire
    Jan 20220152Highwire
    Feb 20220131Highwire
    Mar 20221108Highwire
    Apr 2022045Highwire

    Letters: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    If you are uploading a letter concerning an article:
    You must have updated your disclosures within six months: http://submit.neurology.org

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top

    Related Articles

    Alert Me

    Advertisement